Status:
COMPLETED
Study of Intracellular Nucleotide Pools Determination as Biomarker of the Efficacy of the Induction Treatment in Acute Myeloid Leukemia
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Acute Myeloid Leukemia
Eligibility:
All Genders
18-65 years
Brief Summary
Treatment of acute myeloid leukemia (AML) consists in two main phases: induction and consolidation. Standard chemotherapy combination for induction treatment associates cytarabine (AraC), a nucleoside...
Eligibility Criteria
Inclusion
- Patients
- age over 18 years
- acute myeloid leukemia
- standard induction chemotherapy with cytarabine and daunorubicin
- patients who received the information and did not object to participate to the study
- Patients
Exclusion
- \- patients with acute myeloid leukemia 3
- healthy volunteers Inclusion Criteria :
- adults without known hematological disease,
- adults who received the information and did not object to participate in the study
- healthy volunteers Exclusion Criteria :
- \- Volunteers with known hematological disease.
Key Trial Info
Start Date :
July 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 25 2021
Estimated Enrollment :
83 Patients enrolled
Trial Details
Trial ID
NCT03234985
Start Date
July 1 2017
End Date
October 25 2021
Last Update
November 15 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Service d'hématologie - Centre Hospitalier Lyon Sud - Hospices Civils de LYON
Pierre-Bénite, France, 69495